Coronavirus Infections: Clinical Trials

1,513 trials for Coronavirus Infections, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

693 completed, 334 unknown, 255 terminated, 139 withdrawn. 1513 Phase 2, 278 Phase 3, 268 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 21513Completed 693, Unknown 334, Terminated 255, Withdrawn 139, Recruiting 42, Active not recruiting 26, Not yet recruiting 13, Suspended 8, Enrolling by invitation 3
Phase 3278Completed 109, Unknown 81, Terminated 50, Withdrawn 25, Recruiting 4, Suspended 4, Active not recruiting 3, Not yet recruiting 2
Phase 1268Completed 133, Unknown 66, Terminated 27, Withdrawn 25, Recruiting 10, Active not recruiting 4, Not yet recruiting 3

Follow Coronavirus Infections: new trials by email Literature Review of Coronavirus Infections trials Research Report on Coronavirus Infections

Trials (filtered) newest first · largest first

All 1,513 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Evaluation of the Safety and Efficacy of XoGlo Pro, a Placental Mesenchymal Stem Cell-derived Extracellular Vesicles in Treating COVID-19 Symptoms
IV infusion using an isolated, placental, mesenchymal stem cell derived EVs, Placebo IV administration - COVID-19
Phase 1 / Phase 2Not yet recruitingKimera Labs Inc.642027-01-012026-06-24
Taurine Supplementation in Adolescents With Post-COVID Condition
Taurine - Long COVID, Post COVID-19 Condition
Phase 1 / Phase 2Not yet recruitingUniversity of Alberta302026-12-302026-10-16
CD19-B Cell Depletion in PAIS-ME/CFS Patients
Inebilizumab, Placebo - Post-acute Infectious Syndrome (PAIS), Post-COVID 19 Condition (PCC or Long COVID)
Phase 2Not yet recruitingCharite University, Berlin, Germany382026-12-012026-07-24
Rimonabant for Cognitive Impairment in People With Post-COVID-19 Syndrome
Rimonabant, Placebo - Post-COVID-19 Syndrome
Phase 2Not yet recruitingSinfatin S.L802026-11-062026-11-12
SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction
Valacyclovir, Celecoxib, Paxlovid - Post-acute Sequelae of COVID-19, Long COVID
Phase 2RecruitingIcahn School of Medicine at Mount Sinai1502026-10-202026-10-28
Post-acute Infectious Syndrome - Aripiprazole Symptom Evaluation (PAIS-AriSE)
Aripiprazole (low-dose, 1mg), Placebo - Post-acute Infectious Syndrome (PAIS), Post-COVID-19 Condition (PCC or Long COVID)
Phase 2Not yet recruitingChristiana Franke1382026-10-012026-07-20
Study of VYD2311 for the Treatment of Adults With Long-COVID or Post-Vaccination Syndrome
VYD2311, Placebo - Long COVID, COVID-19 (SARS-CoV-2 Infection)
Phase 2Not yet recruitingInvivyd, Inc.1302026-10-012026-10-27
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of Age
mRNA-1283, mRNA-1273 - SARS-CoV-2
Phase 2RecruitingModernaTX, Inc.3002026-09-042026-11-09
A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID
Maraviroc (MVC), Atorvastatin, 10mg, 20mg, 40mg, Placebo, Maraviroc - Long COVID
Phase 2 / Phase 3Not yet recruitingHealthBio, Inc.2522026-07-152026-06-18
Use of hUC-MSC Product (BX-U001) for the Treatment of COVID-19 With ARDS
Human umbilical cord mesenchymal stem cells + best supportive care, Placebo control + best supportive care - COVID-19, ARDS
Phase 1 / Phase 2WithdrawnBaylx Inc.2026-06-012025-12-29
Evaluating the Safety and Efficacy of PNMR as Treatment for Long COVID
Paragon Novel Metabolic Regulator (PNMR), Dietary and Lifestyle Recommendations - Long COVID
Phase 2RecruitingParagonClinicals Inc.822026-05-202026-06-04
DMSO Dual-Route Therapy for Refractory Tinnitus in Long-COVID and Post-COVID-19 Vaccine Injury
DMSO-based otic solution with betahistine, dexamethasone, and lidocaine, DMSO-based transdermal cream with levocarnitine and N-acetylcysteine - Tinnitus
Phase 2Enrolling by invitationLeading Edge Clinic202026-05-152026-05-13
Sonlicromanol in Post-COVID
Sonlicromanol, Placebo - Post COVID Condition
Phase 2RecruitingMichele van Vugt802026-04-032026-08-18
Direct Topical Lung T3 Treatment to Improve Outcome & Sequelae of COVID-19 Acute Respiratory Distress Syndrome
Instilled T3, Placebo Therapy - Covid19, SARS-CoV Infection
Phase 2WithdrawnUniversity of Minnesota2026-01-152026-02-10
Immunoadsorption in Autoimmune Long COVID
Immunoadsorption, Sham Comparator - Long COVID, Long COVID Syndrome
Phase 2RecruitingAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)702026-01-012026-11-10
Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS
To Measure levels of circulating monocyte/ T cell doublets at Baseline, To measure levels of circulating monocyte/ T cell doublets after 28 days of 2 HOBA treatment, To measure levels of circulating monocyte/ T cell doublets after 28 days of Placebo treatment - Post-Acute COVID-19 Syndrome, Postural Tachycardia Syndrome (POTS)
Phase 2RecruitingVanderbilt University Medical Center502025-12-182026-01-22
"Efesovir" (FS-1) for COVID-19, Phase 2
Efesovir - Covid19
Phase 2Not yet recruitingScientific Center for Anti-infectious Drugs, Kazakhstan622025-12-012024-04-17
Taurine Supplementation in Long COVID
Taurine, Placebo - Long COVID
Phase 2 / Phase 3RecruitingUniversity of Alberta3002025-11-182026-09-18
A Study to Assess Anktiva in Patients With Long Covid-19.
N-803 (IL-15 Superagonist) - Long COVID
Phase 2RecruitingImmunityBio, Inc.202025-11-142026-05-11
Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults
NDV-HXP-S-KP.2, COVID-19 mRNA Vaccine - COVID-19
Phase 2Active not recruitingCastleVax Inc.2002025-11-032026-07-22

Showing 20 of 1513. Sign in to see all of them.

Narrower conditions

COVID-19 (1391)  ·  Post-Acute COVID-19 Syndrome (94)  ·  Respiratory Distress Syndrome (80)  ·  Severe Acute Respiratory Syndrome (78)  ·  Pneumonia (72)  ·  Virus Diseases (41)  ·  Cytokine Release Syndrome (39)  ·  Pneumonia, Viral (32)  ·  Respiratory Insufficiency (26)  ·  Influenza, Human (17)  ·  Acute Lung Injury (16)  ·  Infections (15)  ·  Respiratory Tract Infections (15)  ·  Anosmia (13)

Broader conditions

Nidovirales Infections (1508)  ·  Coronaviridae Infections (1507)  ·  RNA Virus Infections (1505)  ·  Infections (1498)  ·  Respiratory Tract Diseases (1476)  ·  Virus Diseases (1472)  ·  Respiratory Tract Infections (1461)  ·  Lung Diseases (1455)  ·  Pneumonia, Viral (1427)  ·  Pneumonia (1390)  ·  Pathological Conditions, Signs and Symptoms (222)  ·  Pathologic Processes (194)  ·  Disease Attributes (119)  ·  Respiration Disorders (106)

Interventions

Standard of Care (78)  ·  Hydroxychloroquine (65)  ·  Saline Solution (46)  ·  Sodium Chloride (46)  ·  BNT162 Vaccine (39)  ·  Ivermectin (27)  ·  Ritonavir (25)  ·  2019-nCoV Vaccine mRNA-1273 (24)  ·  Azithromycin (24)  ·  remdesivir (18)  ·  nitazoxanide (17)  ·  favipiravir (16)  ·  COVID-19 Serotherapy (15)  ·  COVID-19 Vaccines (15)  ·  ChAdOx1 nCoV-19 (15)

Sponsors

Sinocelltech Ltd. (17)  ·  Sorrento Therapeutics, Inc. (15)  ·  Assistance Publique - Hôpitaux de Paris (14)  ·  BioNTech SE (13)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (13)  ·  Novavax (11)  ·  Pfizer (11)  ·  ModernaTX, Inc. (10)  ·  Stanford University (10)  ·  Washington University School of Medicine (10)  ·  Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation (9)  ·  AstraZeneca (8)  ·  Massachusetts General Hospital (8)  ·  The University of Hong Kong (8)  ·  ANRS, Emerging Infectious Diseases (7)

Countries

United States (516)  ·  Brazil (103)  ·  Spain (87)  ·  China (83)  ·  Mexico (60)  ·  France (59)  ·  Canada (56)  ·  United Kingdom (55)  ·  Italy (54)  ·  Germany (51)  ·  Russia (49)  ·  South Africa (48)  ·  Argentina (37)  ·  South Korea (31)  ·  Colombia (30)

Top investigators

Mike Royal, MD (14)  ·  Teresa Prat (6)  ·  Mikhail Samsonov (5)  ·  Fengcai Zhu, Doctor (4)  ·  Ivan FN Hung, MD FRCP (4)  ·  Lorenzo Berra, MD (4)  ·  Bill Arana (3)

Results publications

PMID 34473343, PMID 35713300, PMID 34013969, PMID 36734509, PMID 37162745, PMID 35244208, PMID 34658014, PMID 31986264, PMID 32031570, PMID 32171076, PMID 32109013, PMID 32142651, PMID 33502773, PMID 39903535, PMID 32192578, PMID 32788708, PMID 33044747, PMID 40592258, PMID 29515037, PMID 32112977, PMID 32205204, PMID 32251768, PMID 32738928, PMID 33306989, PMID 33617777, PMID 33754144, PMID 36700518, PMID 37489818, PMID 38077399, PMID 41720282, PMID 11756340, PMID 11960602, PMID 12086935, PMID 15141377, PMID 16308421, PMID 17941868, PMID 22974412, PMID 23053510, PMID 23208422, PMID 25030060, PMID 29859173, PMID 31978293, PMID 31986257, PMID 32020029, PMID 32085846, PMID 32091533, PMID 32125455, PMID 32150618, PMID 32167524, PMID 32171740

NIH funding

2023 (8), P30CA033572 (3), 2025 (2), UL1TR001412 (2), 1ZIDES102465 (1), 2017 (1), 2019 (1), 272201800011C-P00005-9999-1 (1), 2UG1CA189859-06 (1), 3UH3DK114920-04S2 (1), 5UM1AI148684-02 (1), 5UM1AI148684-03 (1), I21RX004409 (1), P30CA013330 (1), P30CA138292 (1)